• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Lucid Group Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

    7/12/23 12:53:33 PM ET
    $ABCL
    $ADIL
    $ARDS
    $ARTW
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABCL alert in real time by email

    Gainers

    • Healthcare Triangle, Inc. (NASDAQ:HCTI) shares climbed 171.2% to $8.84 as the company launched initiative to prevent ransomware attacks in the $35 billion healthcare data market.
    • Ault Alliance, Inc. (NYSE:AULT) gained 73.3% to $5.72 after the company said it anticipates $200 million in annual revenue for 2023.
    • Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares climbed 67.3% to $11.34 after the company announced collaboration and a $50 million investment from NVIDIA.
    • Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) shares surged 45.1% to $2.5239 after gaining 15% on Tuesday.
    • Liminal BioSciences Inc. (NASDAQ:LMNL) rose 39.6% to $8.31 after the company announced it entered into an arrangement agreement with Structured Alpha LP. Liminal minority shareholders are to receive $8.50 in cash per share in "go private" transaction.
    • AVROBIO, Inc. (NASDAQ:AVRO) surged 38.8% to $1.36 after the company announced plans to explore strategic alternatives.
    • LivePerson, Inc. (NASDAQ:LPSN) shares climbed 33.7% to $5.70 after the company announced a planned CEO transition.
    • InspireMD, Inc. (NYSE:NSPR) gained 31% to $3.03.
    • Daktronics, Inc. (NASDAQ:DAKT) rose 30.4% to $7.97 following better-than-expected fourth-quarter results.
    • Freeline Therapeutics Holdings plc (NASDAQ:FRLN) shares jumped 28.7% to $4.7759.
    • Society Pass Incorporated (NASDAQ:SOPA) gained 23.6% to $0.7490. Ascendiant Capital recently initiated coverage on Society Pass with a Buy rating and announced a price target of $3.5.
    • Holley Inc. (NYSE:HLLY) surged 21.6% to $5.35 on positive analyst changes. B of A Securities upgraded the stock and raised its price target from $3.25 to $6, and JP Morgan upgraded the stock from Overweight to Neutral and announced a $7 price target.
    • Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) rose 21% to $0.3240 after the company announced FDA Qualified Infectious Disease Product Designation for AR-301.
    • Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) gained 20.4% to $9.13. Eloxx Pharmaceuticals shares jumped 94% on Tuesday after Oppenheimer raised its price target from $50 to $55.
    • AERWINS Technologies Inc. (NASDAQ:AWIN) jumped 17% to $0.55.
    • Centessa Pharmaceuticals plc (NASDAQ:CNTA) rose 15.8% to $8.46. Centessa Pharmaceuticals recently announced dosing of first subject in registrational PRESent-2 study evaluating SerpinPC for the treatment of Hemophilia B without inhibitors.
    • EHang Holdings Limited (NASDAQ:EH) gained 13.5% to $17.54. EHang announced a $23 million private placement led by investor Lee Soo Man.
    • AbCellera Biologics Inc. (NASDAQ:ABCL) gained 13% to $7.63.
    • BitNile Metaverse, Inc. (NASDAQ:BNMV) surged 12.2% to $1.1899.
    • Exscientia plc (NASDAQ:EXAI) rose 12% to $7.30. Exscientia recently announced the enrollment of the first patient in the Phase 1/2 "ELUCIDATE" clinical trial assessing GTAEXS617 in advanced solid tumors.
    • Domino's Pizza, Inc. (NYSE:DPZ) shares surged 10.2% to $385.54 after the company announced US customers will be able to order through Uber Eats and Postmates.
    • Art's-Way Manufacturing Co., Inc. (NASDAQ:ARTW) gained 9.7% to $2.71.
    • Dada Nexus Limited (NASDAQ:DADA) jumped 7.3% to $6.22.

    Losers

    • PainReform Ltd. (NASDAQ:PRFX) declined 44.5% to $9.00 after the company reported pricing of $2.7 million concurrent registered direct offering and private placement.
    • CBL International Limited (NASDAQ:BANL) shares dipped 42.3% to $2.8780 after jumping over 12% on Tuesday.
    • Katapult Holdings, Inc. (NASDAQ:KPLT) declined 27% to $0.7150. Katapult’s board approved a 1-for-25 reverse stock split of common stock.
    • Silk Road Medical, Inc (NASDAQ:SILK) fell 24.4% to $24.67. Silk Road Medical is expected to report financial results for the second quarter 2023 on Aug. 1, 2023.
    • Yellow Corporation (NASDAQ:YELL) dropped 21.5% to $1.0350.
    • Gorilla Technology Group Inc. (NASDAQ:GRRR) fell 20% to $4.46.
    • T2 Biosystems, Inc. (NASDAQ:TTOO) dropped 20% to $0.1196 as the company reported lower than expected preliminary Q2 sales of $2 million.
    • Theratechnologies Inc. (NASDAQ:THTX) declined 19.5% to $0.78 following weak quarterly sales.
    • Castle Biosciences, Inc. (NASDAQ:CSTL) fell 19.3% to $15.89.
    • Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) fell 17.7% to $4.9655 after surging 42% on Tuesday.
    • Crown ElectroKinetics Corp. (NASDAQ:CRKN) fell 16.1% to $0.0913 after gaining around 7% on Tuesday.
    • Jupiter Wellness, Inc. (NASDAQ:JUPW) dropped 15.4% to $0.4052. Jupiter Wellness reported postponement of spin-off and distribution of common stock of subsidiary SRM Entertainment.
    • Forge Global Holdings, Inc. (NYSE:FRGE) fell 14.7% to $2.43.
    • Mullen Automotive, Inc. (NASDAQ:MULN) fell 14.6% to $0.1554.
    • Shengfeng Development Limited (NASDAQ:SFWL) dropped 14% to $7.87.
    • ShiftPixy, Inc. (NASDAQ:PIXY) fell 13.8% to $2.06 after the company announced pricing of a $3.1 million public offering.
    • CytoMed Therapeutics Limited (NASDAQ:GDTC) shares dropped 13.1% to $4.90 after climbing 62% on Tuesday.
    • FLJ Group Limited (NASDAQ:FLJ) fell 12.8% to $0.2510.
    • Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) shares fell 11.7% to $0.34. Adial Pharmaceuticals shares jumped 90% on Tuesday after the company provided business update following favorable comments from US, EU regulatory meetings.
    • Lucid Group, Inc. (NASDAQ:LCID) declined 10.9% to $7.24 after the company announced second-quarter production & deliveries.
    • Cingulate Inc. (NASDAQ:CING) fell 10.4% to $0.76. Cingulate recently announced top-line results from its Phase 3 adult efficacy and safety trial of CTx-1301 for ADHD.
    • WANG & LEE GROUP, Inc. (NASDAQ:WLGS) shares fell 9.7% to $1.40 after rising over 20% on Tuesday.
    • COMPASS Pathways plc (NASDAQ:CMPS) fell 7.5% to $9.30.

     

    Now Read This: Big Trades On Activision Blizzard Stock After Microsoft Wins Acquisition Case

    Get the next $ABCL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABCL
    $ADIL
    $ARDS
    $ARTW

    CompanyDatePrice TargetRatingAnalyst
    COMPASS Pathways Plc
    $CMPS
    4/24/2026$17.00Buy
    B. Riley Securities
    Centessa Pharmaceuticals plc
    $CNTA
    4/13/2026$38.00Buy → Hold
    Truist
    Lucid Group Inc.
    $LCID
    3/18/2026$17.00Buy
    Citigroup
    Lucid Group Inc.
    $LCID
    3/4/2026$10.00Underperform
    BofA Securities
    Centessa Pharmaceuticals plc
    $CNTA
    2/24/2026$40.00Outperform
    Wolfe Research
    Domino's Pizza Inc
    $DPZ
    2/24/2026$450.00Neutral → Overweight
    Analyst
    InspireMD Inc.
    $NSPR
    2/2/2026$6.00Buy
    Maxim Group
    Domino's Pizza Inc
    $DPZ
    1/20/2026$455.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $ABCL
    $ADIL
    $ARDS
    $ARTW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher

    Compass is the most advanced company in classic psychedelics and has generated positive data from two ongoing large, well controlled Phase 3 clinical trials, designed to uphold the highest regulatory standards FDA grants Compass NDA rolling submission and review request, based on Phase 3 data CNPV awarded for COMP360, Compass' proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD) CNPV further accelerates momentum and Compass is confident and ready to deliver for patients Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S

    4/24/26 10:37:00 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Healthcare Triangle, Inc. Launches AI-Driven Digital Self-Care Therapy Platform "ZoraNex" to address the $450B Global Mental Health Market

    Positioning this new platform at the intersection of AI, healthcare delivery, and preventive wellness for Its Global Healthcare Expansion StrategyPLEASANTON, Calif., April 23, 2026 /CNW/ -- Healthcare Triangle, Inc. (NASDAQ:HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions for healthcare and life sciences, today announced the launch of ZoraNex, an AI-driven digital self-care therapy platform developed under its wholly owned subsidiary, QuantumNexis Inc ("QuantumNexis"). The launch represents a key milestone in the Company's broader strategy to build a scalable, AI-powered healthcare ecosystem across global markets, with a particular focus on Southeast Asia as a co

    4/23/26 8:05:00 AM ET
    $HCTI
    EDP Services
    Technology

    Holley Performance Brands Expands Fan Experiences for 2026 Flagship Event Season

    NASHVILLE, Tenn., April 23, 2026 (GLOBE NEWSWIRE) -- Holley Performance Brands (NYSE:HLLY), home to a portfolio of iconic automotive brands serving enthusiasts across the high-performance aftermarket, has announced its 2026 flagship event season, which begins this week with LS Fest West at Las Vegas Motor Speedway. Following a strong 2025 season that drew more than 105,000 attendees across Holley's flagship events and generated over 75 million social media impressions, the company is expanding its 2026 lineup with new premium activations and enhanced fan experiences designed to deepen engagement and strengthen brand reach. Holley's flagship events remain a cornerstone of the company's exp

    4/23/26 6:00:00 AM ET
    $HLLY
    Auto Parts:O.E.M.
    Consumer Discretionary

    $ABCL
    $ADIL
    $ARDS
    $ARTW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Thermopylae Holdings Ltd. bought $130,720 worth of shares (38,000 units at $3.44), increasing direct ownership by 0.07% to 56,134,097 units (SEC Form 4)

    4 - AbCellera Biologics Inc. (0001703057) (Issuer)

    3/2/26 2:16:40 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Thermopylae Holdings Ltd. bought $580,284 worth of shares (177,457 units at $3.27), increasing direct ownership by 0.32% to 56,096,097 units (SEC Form 4)

    4 - AbCellera Biologics Inc. (0001703057) (Issuer)

    2/27/26 4:20:01 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Booth Andrew bought $145,692 worth of shares (42,600 units at $3.42), increasing direct ownership by 28% to 195,600 units (SEC Form 4)

    4 - AbCellera Biologics Inc. (0001703057) (Issuer)

    2/27/26 2:48:34 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABCL
    $ADIL
    $ARDS
    $ARTW
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Recursion Pharmaceuticals Inc.

    SCHEDULE 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

    4/24/26 4:11:56 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Domino's Pizza Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - DOMINOS PIZZA INC (0001286681) (Filer)

    4/24/26 4:05:16 PM ET
    $DPZ
    Food Distributors
    Consumer Discretionary

    SEC Form DEFA14A filed by Lucid Group Inc.

    DEFA14A - Lucid Group, Inc. (0001811210) (Filer)

    4/23/26 6:47:55 PM ET
    $LCID
    Auto Manufacturing
    Industrials

    $ABCL
    $ADIL
    $ARDS
    $ARTW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on COMPASS Pathways with a new price target

    B. Riley Securities initiated coverage of COMPASS Pathways with a rating of Buy and set a new price target of $17.00

    4/24/26 8:18:00 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Centessa Pharmaceuticals downgraded by Truist with a new price target

    Truist downgraded Centessa Pharmaceuticals from Buy to Hold and set a new price target of $38.00

    4/13/26 8:43:07 AM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Lucid Group with a new price target

    Citigroup initiated coverage of Lucid Group with a rating of Buy and set a new price target of $17.00

    3/18/26 8:56:23 AM ET
    $LCID
    Auto Manufacturing
    Industrials

    $ABCL
    $ADIL
    $ARDS
    $ARTW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gibson Christopher converted options into 40,000 shares and sold $144,400 worth of shares (40,000 units at $3.61) as part of a pre-agreed trading plan (SEC Form 4)

    4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

    4/24/26 4:23:14 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Lopez Patricia E was granted 515 shares, increasing direct ownership by 18% to 3,342 units (SEC Form 4)

    4 - DOMINOS PIZZA INC (0001286681) (Issuer)

    4/23/26 6:48:44 PM ET
    $DPZ
    Food Distributors
    Consumer Discretionary

    Director Kramer Stephen Howard was granted 515 shares, increasing direct ownership by 150% to 859 units (SEC Form 4)

    4 - DOMINOS PIZZA INC (0001286681) (Issuer)

    4/23/26 6:48:27 PM ET
    $DPZ
    Food Distributors
    Consumer Discretionary

    $ABCL
    $ADIL
    $ARDS
    $ARTW
    Leadership Updates

    Live Leadership Updates

    View All

    Gorilla Technology Increases Strategic Investment in Astrikos.AI

    - Builds on Q4 investment to further advance Gorilla's integrated AI infrastructure strategy across India, USA, and UAE- Appoints Managing Partner of Gorilla Tech Capital to the board of AstrikosLondon, United Kingdom--(Newsfile Corp. - April 15, 2026) - Gorilla Technology Group Inc. (NASDAQ:GRRR) ("Gorilla" or the "Company"), a global solution provider in AI-driven Security Intelligence, Network Intelligence, Business Intelligence and IoT technology, today announced that it has increased its strategic investment in Astrikos.AI ("Astrikos"), the Bengaluru, India-based, real-time infrastructure intelligence company, deepening the operational and commercial relationship betw

    4/15/26 8:30:00 AM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    Lucid Names Global Industrial Leader Silvio Napoli as Next Chief Executive Officer to Accelerate Growth, Profitability and Value Creation

    Silvio Napoli, formerly Chairman and Chief Executive Officer of Schindler Group, to join Lucid as next Chief Executive OfficerInterim Chief Executive Officer Marc Winterhoff will continue as Chief Operating Officer upon Napoli assuming the roleNEWARK, Calif., April 14, 2026 /PRNewswire/ -- Lucid Group, Inc. (NASDAQ:LCID), maker of the world's most advanced software-defined vehicles and technologies, today announced that Silvio Napoli will be Lucid's next Chief Executive Officer (CEO) and will join Lucid's Board of Directors. Mr. Napoli is currently based in Switzerland and will be relocating to the U.S. Interim Chief Executive Officer Marc Winterhoff will serve as Lucid's Chief Operating Off

    4/14/26 7:00:00 AM ET
    $LCID
    Auto Manufacturing
    Industrials

    Preliminary Results for the Year Ended 31 December 2025

    March 27, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces its audited preliminary results for the year ended 31 December 2025. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFOTel: +44 (0)29 2048 0180www.biodexapharma.com About Biodexa The Company's lead development programs include eRapa, under development for Familial Adenoma

    3/27/26 5:00:00 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABCL
    $ADIL
    $ARDS
    $ARTW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Daktronics Inc.

    SC 13D/A - DAKTRONICS INC /SD/ (0000915779) (Subject)

    12/11/24 5:00:16 PM ET
    $DAKT
    Miscellaneous manufacturing industries
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Gorilla Technology Group Inc.

    SC 13G/A - Gorilla Technology Group Inc. (0001903145) (Subject)

    12/6/24 9:25:12 PM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G filed by InspireMD Inc.

    SC 13G - InspireMD, Inc. (0001433607) (Subject)

    12/4/24 4:31:06 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $ABCL
    $ADIL
    $ARDS
    $ARTW
    Financials

    Live finance-specific insights

    View All

    Katapult to Announce First Quarter 2026 Financial Results on May 7, 2026

    PLANO, Texas, April 23, 2026 (GLOBE NEWSWIRE) -- Katapult Holdings, Inc. (NASDAQ:KPLT), an e-commerce-focused financial technology company, today announced it will release its first quarter 2026 financial results before the market opens on Thursday, May 7, 2026. In light of the pending merger with The Aaron's Company and CCF Holdings LLC, Katapult is not hosting a conference call to discuss first quarter 2026 financial results. All materials related to the company's financial disclosure will be available on the Katapult Investor Relations website at http://ir.katapultholdings.com/. About Katapult Katapult is a technology driven lease-to-own platform that integrates with omni-channel ret

    4/23/26 6:00:00 AM ET
    $KPLT
    Diversified Commercial Services
    Consumer Discretionary

    Holley Performance Brands to Release First Quarter 2026 Results on May 6, 2026

    NASHVILLE, Tenn., April 22, 2026 (GLOBE NEWSWIRE) -- Holley Performance Brands (NYSE:HLLY), a leader in automotive aftermarket performance solutions, today announced the date for the release of its first quarter 2026 financial results. First Quarter 2026 ResultsHolley will host a conference call and live webcast on Wednesday, May 6, 2026, at 8:30 am (Eastern Time) to discuss the Company's first quarter 2026 financial results. The Company's earnings release and presentation for the first quarter 2026 will be issued before the market opens on Wednesday, May 6, 2026, and will be available on the Investor Relations page of the Company's website at investor.holley.com. Hosting the call will b

    4/22/26 8:35:00 AM ET
    $HLLY
    Auto Parts:O.E.M.
    Consumer Discretionary

    AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

    AbCellera (NASDAQ:ABCL) today announced that it will disclose interim results from the Phase 1 portion of its study of ABCL635, including observed safety profile, pharmacokinetic, and pharmacodynamic target engagement data, during its first quarter 2026 earnings call on Monday, May 11, 2026. ABCL635 is a potential first-in-class antibody therapeutic targeting the neurokinin 3 receptor (NK3R) for the non-hormonal treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. It is currently being evaluated in a Phase 1/2 study, and the results of the ongoing multicenter, randomized, double-blind, placebo-controlled Phase 2 portion in postmenopausal women with moderate-

    4/20/26 9:00:00 AM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care